this article describes the financial and business updates of acorda therapeutics, a new drug for the treatment of Parkinson. we describe the growth of acorda in the first half of 2023 and the impact of the new sales and marketing programs that we launched. we believe that full year, we expect to be lower than our guidance at the beginning of the year, and we are therefore updating our 2023 guidance to between $34 million to 38 from our original guidance range of $38 million to 42 million. we expect our ending cash balance to be between $39 million and 42 million versus the original 43 million to $47 million.